Hepatitis C related Press Releases
MIT: Stem cells could drive hepatitis research forward
MIT: Stem cells could drive hepatitis research forwardBy creating liver-like cells, scientists can study why people respond differently to the disease CAMBRIDGE, Mass. -- Hepatitis C, an infectious Read more...
BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C
JERUSALEM--(BUSINESS WIRE)-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a Read more...
First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published
First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy PublishedStudy also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment Read more...
Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achiev
PETAH-TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Read more...
The Hepatitis C Virus Drug Market Will Experience Dramatic Near-Term Growth, Increasing from $1.7 Billion in 2010 to $16 B
After 2015, the Market Will Decrease to $11.3 Billion in 2020, Owing to a Decline in the Size of the Treatment-Eligible Population, According to Findings from Decision Resources BURLINGTON, Mass.--( Read more...
All-Oral Treatment Regimen of Bristol-Myers Squibb’s Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virolo
Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patientsStudy expanded to include alfa/RBV Read more...
Vertex Announces Webcasts of Two Investor Presentations
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex will webcast its company presentation at its investor event from San Francisco at Read more...
PURE Bioscience Reports Fourth Quarter and Fiscal Year 2011 Results
Conference Call begins Today at 4:30 p.m. Eastern time SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today Read more...
Inhibitex to Host Conference Call to Report Third Quarter Financial Results on November 4, 2011
ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Friday, November 4, 2011 at 9:00 a.m. EDT to review the Company’s third quarter Read more...
Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment
FOSTER CITY, Calif. & LOUISVILLE, Colo.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) and GlobeImmune, Inc. today announced that the companies have entered into an exclusive worldwide Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
